Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07212751

Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)

The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Nonfatal Stroke All-cause Death Arterial Occlusive Diseases Arteriosclerosis Brain Diseases CT Plaque Calcified Plaque Cardiovascular Death Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Chest Pain Coronary Artery Disease Coronary Disease FFR-CT Heart Diseases Myocardial Ischemia Nervous System Diseases Neurologic Manifestations Non-calcified Plaque Nonfatal Myocardial Infarction Pain Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Plaque, Amyloid Signs and Symptoms Stroke Stroke (Subacute) Vascular Diseases

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Hong Kong

Hong Kong

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
  • If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Exclusion criteria

  • Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated glomerular filtration rate <30 mL/min), major allergy to contrast.

Treatment and study plan

CTCA

Diagnostic Test

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment

  • If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Primary outcomes

  1. Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death

    Time frame: 5 years after CTCA examinations

Secondary outcomes

  1. Total plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  2. Calcified plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  3. Non-calcified plaque (mm³) to predict cardiac events

    Time frame: 5 years after CTCA examinations

  4. CT-FFR to predict cardiac events

    Time frame: 5 years after CTCA examinations

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Acronym: CT-PLAQUE

Important dates

Study start
2020
Primary completion
2026
Study completion
2027
First posted
Oct 8, 2025
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.